Hepatic metabolomics of the compatibility effect of Xiaoyaosan on CUMS-induced depression based on the TCM theory of Treating Diseases via Regulating the Liver's Function

This study aimed to demonstrate the scientific connotations and compatibility effects of Xiaoyaosan (XYS) based on the theory of Treating Diseases via Regulating the Liver's Function by hepatic metabolomics. XYS was divided into two efficacy groups, i.e. the Shugan (SG) and the Jianpi (JP) groups, according to the strategy of Efficacy Compositions. The chronic unpredictable mild stress (CUMS) depression model was constructed. A H-1 NMR-based hepatic metabolomics approach coupled with multivariate data (MVD) analysis was performed. Meanwhile, relative distance (RD) and Efficacy Index (EI) were calculated. XYS and its efficacy groups significantly reversed the abnormality of behavior and hepatic metabolomics of depression rats, but to different degrees. The results of ethology and metabolomics showed the same order, i.e. XYS > JP > SG. Two metabolites, i.e. tyrosine and malate, were regulated by all the treatment groups. Four metabolites were significantly regulated only by XYS group. Of note, the results showed the two efficacy groups of XYS exhibited synergistic anti-depression effects, and glutamate, malate and taurine could be the key hepatic metabolites for these synergistic effects. The current study not only complements and consummates the mechanisms of depression and the anti-depression effects of XYS from the perspective of hepatic metabolomics, but also lays a solid foundation for comprehensively and deeply understanding the compatibility effects of XYS against depression, especially from the points of view of compatibility in Traditional Chinese medicine (TCM) theory and synergism in modern medicine theory. (C) 2021 Elsevier B.V. All rights reserved.

Automated summary

This study demonstrated the scientific significance and compatibility effects of Xiaoyaosan (XYS) based on hepatic metabolomics. XYS and its efficacy groups effectively reversed the abnormal behavior and hepatic metabolomics of depression rats, with the two efficacy groups of XYS showing synergistic anti-depression effects. Certain metabolites such as glutamate, malate, and taurine may play key roles in these synergistic effects.